Arcadia Biosciences Inc (RKDA)
Official siteCONSUMER DEFENSIVE • PACKAGED FOODS • NASDAQ
Market Cap: $1.32M
Last updated: Nov 17, 2026 at 11:04 AM ET
Arcadia Biosciences Inc (RKDA) Financials: Revenue, Profit and Cash Flow
Arcadia Biosciences reported revenue of $4.86M for the fiscal year ended Dec 31, 2025, down 3.7% from the year before. That year, net income was -$2.34M with a net margin of -48.1%, operating cash flow was -$4.74M and free cash flow was -$4.74M. The quarter ended Sep 30, 2026 had revenue of $1.62M and net income of $1.75M.
Revenue and Margins
The operating margin was -51.5% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $3.19M, a compound annual rate of 4.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $4.86M | -3.7% | 36.2% | -51.5% | -48.1% |
| Dec 2024 | $5.04M | +13.3% | 41.3% | -72.3% | -139.5% |
| Dec 2023 | $4.45M | -40.0% | 51.2% | -137.0% | -314.0% |
| Dec 2022 | $7.42M | +9.4% | 17.8% | -188.8% | -210.5% |
| Dec 2021 | $6.78M | -15.6% | -28.4% | -524.0% | -238.0% |
| Dec 2020 | $8.03M | +587.3% | 35.3% | -159.0% | -75.0% |
| Dec 2019 | $1.17M | -20.2% | 24.3% | -1657.9% | -2469.9% |
| Dec 2018 | $1.46M | -63.6% | 100.0% | -1152.3% | -1841.5% |
| Dec 2017 | $4.03M | +26.3% | 100.0% | -355.6% | -390.1% |
| Dec 2016 | $3.19M | N/A | 71.9% | -584.1% | -615.6% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income rose 104.4% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.86M | $5.04M | $4.45M | $7.42M | $6.78M | $8.03M | $1.17M | $1.46M | $4.03M | $3.19M |
| Cost of revenue | $3.10M | $2.96M | $2.17M | $6.10M | $8.71M | $5.20M | $885.00K | $0 | $0 | $895.00K |
| Gross profit | $1.76M | $2.08M | $2.28M | $1.32M | -$1.93M | $2.83M | $284.00K | $1.46M | $4.03M | $2.29M |
| Research and development | $9.00K | $53.00K | $64.00K | $1.51M | $3.89M | $7.96M | $7.10M | $6.07M | $7.41M | $8.66M |
| Operating income | -$2.50M | -$3.65M | -$6.10M | -$14.01M | -$35.53M | -$12.78M | -$19.38M | -$16.87M | -$14.31M | -$18.62M |
| Net income | -$2.34M | -$7.04M | -$13.99M | -$15.61M | -$16.13M | -$6.03M | -$28.87M | -$26.96M | -$15.71M | -$19.62M |
| EBITDA | -$2.47M | N/A | $1.04M | -$9.74M | -$13.02M | -$3.80M | N/A | -$10.95M | -$13.75M | -$17.64M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.62M | $1.44M | $1.10M | $901.00K | $1.30M | $1.46M | $1.20M | $1.22M | $1.54M | $1.31M | $987.00K | $627.00K |
| Gross profit | $859.00K | $631.00K | $400.00K | $193.00K | $418.00K | $631.00K | $518.00K | $388.00K | $505.00K | $673.00K | $516.00K | $609.00K |
| Operating income | -$839.00K | -$496.00K | -$779.00K | -$1.38M | -$1.15M | -$501.00K | $530.00K | -$2.28M | -$1.76M | $1.98M | -$1.59M | $616.00K |
| Net income | $1.75M | -$6.27M | -$4.38M | -$1.34M | $856.00K | -$4.46M | $2.60M | -$4.06M | -$1.61M | $1.06M | -$2.42M | -$2.85M |
Balance Sheet
As of Dec 2025, cash and equivalents of $259.00K were 4.0% of total assets of $6.55M, against total liabilities of $2.41M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $6.55M | $13.52M | $19.70M | $28.92M | $43.92M | $47.35M | $32.57M | $24.02M | $16.57M | $56.57M |
| Current assets | $6.36M | $9.24M | $14.97M | $25.40M | $35.39M | $31.70M | $28.44M | $22.88M | $15.05M | $52.22M |
| Cash and equivalents | $259.00K | $4.24M | $6.52M | $20.64M | $28.68M | $14.04M | $8.42M | $12.00M | $9.13M | $2.01M |
| Total liabilities | $2.41M | $7.29M | $7.00M | $8.02M | $12.72M | $18.80M | $24.25M | $11.21M | $8.56M | $34.38M |
| Short-term debt | N/A | $155.00K | $852.00K | $1.01M | $1.07M | $1.14M | $24.00K | $29.00K | N/A | $25.13M |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | $2.10M | $107.00K | N/A | $0 | $25.13M |
| Shareholder equity | $4.14M | $6.22M | $12.84M | $21.03M | $31.09M | $27.73M | $7.71M | $12.81M | $8.01M | $22.20M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $4.72M | $5.89M | $5.32M | $6.55M | $8.58M | $7.79M | $12.99M | $13.52M | $15.24M | $17.37M | $16.05M | $19.70M |
| Total liabilities | $2.31M | $5.26M | $2.44M | $2.41M | $3.14M | $3.25M | $4.08M | $7.29M | $5.09M | $5.80M | $5.56M | $7.00M |
| Cash and equivalents | $2.84M | $4.18M | $954.00K | $259.00K | $1.12M | $1.38M | $3.16M | $4.24M | $3.94M | $5.50M | $3.32M | $6.52M |
| Shareholder equity | $2.40M | $633.00K | $2.88M | $4.14M | $5.44M | $0 | $0 | $6.22M | $10.29M | $11.70M | $10.62M | $12.84M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.74M | -$9.63M | -$15.29M | -$13.98M | -$25.87M | -$30.22M | -$17.20M | -$13.63M | -$13.96M | -$17.05M |
| Capital expenditures | $0 | $16.00K | $5.00K | $72.00K | $1.01M | $2.33M | $1.48M | $250.00K | $79.00K | $231.00K |
| Free cash flow | -$4.74M | -$9.64M | -$15.30M | -$14.05M | -$26.88M | -$32.55M | -$18.68M | -$13.88M | -$14.04M | -$17.29M |
| Share repurchases | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1.31M | N/A | N/A |
| Investing cash flow | $750.00K | $7.34M | -$4.34M | $1.42M | $16.61M | $17.28M | -$8.37M | -$5.97M | $47.18M | -$5.30M |
| Financing cash flow | $6.00K | $9.00K | $5.51M | $4.52M | $21.90M | $20.56M | $21.99M | $22.48M | -$26.10M | $396.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.28M | -$319.00K | -$1.10M | -$861.00K | -$257.00K | -$2.03M | -$1.59M | -$2.21M | -$1.75M | -$2.46M | -$3.21M | -$4.14M |
| Capital expenditures | N/A | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $2.00M | $3.00K | $13.00K | $52.00K |
| Free cash flow | N/A | N/A | -$1.10M | -$861.00K | -$257.00K | -$2.03M | -$1.59M | -$2.21M | -$3.75M | -$2.46M | -$3.22M | -$4.20M |
Frequently Asked Questions About RKDA
What is Arcadia Biosciences' annual revenue?
Arcadia Biosciences reported revenue of $4.86M for the fiscal year ended Dec 31, 2025.
How fast is Arcadia Biosciences' revenue growing?
Revenue was down 3.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -13.2%.
Is Arcadia Biosciences profitable?
No. Arcadia Biosciences reported net income of -$2.34M for the fiscal year ended Dec 31, 2025, with a net margin of -48.1%.
How much free cash flow does RKDA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$4.74M minus capital expenditures of $0 produced free cash flow of -$4.74M.
How much debt does Arcadia Biosciences have?
The balance sheet dated Dec 31, 2025 reported cash and equivalents of $259.00K.
RKDA pages: Overview, Earnings, Financials, Valuation, Competitors